News & Analysis as of

Science, Computers & Technology Intellectual Property International Trade

Read Science, Computers & Technology updates, news, alerts, and legal analysis from leading lawyers and law firms:

October 2017: International Trade Update

The Legal Implications of the Use of Blockchain in International Trade. What has become popularly known as “blockchain” is a form of Distributed Ledger Technology (“DLT”). At its core, blockchain is for electronic...more

In Wake of Equifax Breach, Squatters Appear and Are Vanquished

On September 7, Equifax Inc. announced the cyber security breach that could potentially impact 100 million U.S. consumers. In addition to Equifax’s main website, Equifax.com, the company set up a dedicated website —...more

Brexit Bill - Impact on patents

by Hogan Lovells on

The UK government’s draft EU Withdrawal Bill (the “Brexit Bill“) aims to incorporate EU directives and regulations into UK domestic law in their current form immediately following Brexit (“Retained EU Law“).  This article...more

USTR Holds Hearing In Investigation Of China’s Technology Transfer And IP Practices

by King & Spalding on

On August 18, 2017, the United States Trade Representative (USTR) initiated an investigation pursuant to Section 302(b)(1)(A) of the Trade Act of 1974 (Section 301) on certain technology transfer and IP practices of the...more

Boehringer Ingelheim’s First Biosimilar Is Approved in Europe

by Goodwin on

Boehringer Ingelheim (BI) announced today that it received marketing authorization in Europe for Cyltezo®, which is a biosimilar to Humira®. Cyltezo® was approved for the treatment of multiple chronic inflammatory diseases in...more

PTAB Adopts New Attorney-Client Privilege Rule for PTO Trial Proceedings, Extending Protection to Patent Agents and Foreign Patent...

by Goodwin on

Earlier this week the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (“PTAB”) published a Final Rule regarding the scope of the attorney-client privilege in proceedings before the PTAB. The Rule states that...more

Biosimilars Update: Amgen, Allergan, Pfenex, Cinfa

by Goodwin on

Below are regulatory and development updates regarding a number of biosimilar candidates. Today, Amgen and Allergen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...more

Fashion Law Newsletter - November 2017

by K&L Gates LLP on

"In order to be irreplaceable, one must always be different." - Coco Chanel Welcome to our latest edition of Fashion Law where we provide you with the latest updates on legal issues affecting the fashion industry. In...more

Global Patent Prosecution Newsletter - November 2017

An Update on Brazilian Patent Law – Emergency Backlog/Fast-Track Options and Enforcement Issues - We are delighted to have as contributors to the November Global Patent Prosecution newsletter, Ricardo Nunes and Andre...more

“The Cosby Show” Producer Demands BBC Foot The Bill For Using Show Clips In Documentary Exposé

by Fox Rothschild LLP on

Former American icon Bill Cosby has been accused of sexually assaulting at least sixty women over five decades, according to Time Magazine. But the Carsey-Werner Company, which produced Cosby’s hit sitcom “The Cosby Show”,...more

IPunkt - October 2017

by Hogan Lovells on

Kurze Einleitung - Liebe Leserin, lieber Leser, diesen Monat ist es endlich wieder soweit. Der IPunkt kehrt in neuem Gewand zurück. Passend hierzu haben unsere Autoren die neuesten Updates im Bereich des IPMT kurz...more

A Stricter EPO? The EPO Updates its Guidelines for Examination

Effective 1 November 2017, the European Patent Office (EPO) has updated its Guidelines for Examination. While we have already reported the modifications relating to the practice of assignments, here we uncover some of the...more

Updates on Sandoz’s Pegfilgrastim Biosimilar / Amgen v. Sandoz

by Goodwin on

Today, Sandoz announced that its biosimilar of Neulasta® (pegfilgrastim) has been accepted by the European Medicines Agency (EMA) for regulatory review. According to the press release, the data package submitted as part of...more

4 Key Takeaways: The Hague Agreement & Design Filings – Things You Need to Know & Do

Kilpatrick Townsend partner Babak Kusha, along with a panel of other thought leaders, recently presented a Knowledge Group webinar on the topic of “The Hague Agreement and Design Filings.” The Hague Agreement is an...more

USPTO and EPO Examiners Discuss Key Considerations for Filing Effective Precision Medicine and Bioinformatics Applications in the...

At a symposium and webinar presented by Fenwick & West and Mewburn Ellis, we asked U.S. Patent and Trademark Office and European Patent Office examiners to provide perspective on the preparation and prosecution of patent...more

UK Takes One Step Closer Towards Ratification of the Unified Patents Court Agreement

by Allen & Overy LLP on

Before the UK is able to ratify the Unified Patents Court Agreement, statutory instruments establishing the Unified Patents Court as a corporate entity in the UK and granting it certain privileges and immunities (such as...more

Stricter Assessment of Assignment Documents by the EPO

The European Patent Office (EPO) has recently introduced more stringent checking of documents filed in support of a transfer of rights. This will apply whenever the EPO is asked to update its records of the ownership of a...more

Uniloc USA v. Sega of America: Evaluating the Priority Date of a Means + Function Claim

Uniloc USA owns US 5,490,216 (‘216), with claims directed to “[a] registration system for licensing execution of digital data in a use mode….” Sega petitioned for Inter Partes Review of the ‘216 patent, arguing that Claims...more

Compulsory Licensing of Biopharmaceutical Inventions

Very few topics in international intellectual property have been as controversial as compulsory licenses. While the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) sets minimum standards for...more

Global Patent Prosecution Newsletter - October 2017

March-in Rights and Compulsory Licensing of Biopharmaceutical Inventions - Very few topics in international intellectual property have been as controversial as compulsory licensing. In the US, consumer groups have...more

IP and healthcare in South East Asia: “Bigger than BRIC”. So why aren’t you filing your patent applications there?

by FPA Patent Attorneys on

The South East Asian healthcare market is emerging as one of great importance, expected to experience faster rates of healthcare spending growth over the next 5 years than the BRIC (Brazil, Russia, India, China) countries...more

Canada Institutes Certificates of Supplementary Protection for Approved Drug Products

On September 21, 2017, the Comprehensive Economic and Trade Agreement (CETA) signed between the European Union (EU) and Canada provisionally entered into force in Canada.  Among other things, this agreement seeks to harmonize...more

MarkIt to Market® | September 2017

The September 2017 issue of Sterne Kessler's MarkIt to Market® discusses consent agreements, positive developments in the European community, and lists the new gTLD Sunrise periods. Please see full newsletter below for...more

Rx IP Update - September 2017

by Smart & Biggar on

Federal Court of Appeal Applies Supreme Court’s Utility Test to SPRYCEL Patent - In its first decision to consider the Supreme Court of Canada’s landmark decision in AstraZeneca Canada Inc v Apotex Inc, 2017 SCC 36...more

.CH leads the way in the battle against fraud

by Hogan Lovells on

SWITCH, the Registry responsible for the country code Top Level Domain (ccTLD) .CH, recently published an article on the subject of counterfeit goods and fraudulent websites hosted under the .CH ccTLD and the measures they...more

938 Results
|
View per page
Page: of 38
Cybersecurity

Follow Science, Computers & Technology Updates on:

"My best business intelligence,
in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.